John Patrick Darby Sells 14,543 Shares of Encompass Health Co. (NYSE:EHC) Stock

Encompass Health Co. (NYSE:EHC) EVP John Patrick Darby sold 14,543 shares of Encompass Health stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $83.94, for a total transaction of $1,220,739.42. Following the completion of the sale, the executive vice president now owns 84,773 shares in the company, valued at $7,115,845.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Encompass Health Price Performance

EHC stock opened at $85.93 on Wednesday. The company’s 50-day moving average price is $79.33 and its two-hundred day moving average price is $71.79. The firm has a market cap of $8.65 billion, a P/E ratio of 23.22, a P/E/G ratio of 1.30 and a beta of 0.92. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 1.14. Encompass Health Co. has a 12 month low of $57.55 and a 12 month high of $86.60.

Encompass Health (NYSE:EHC) last announced its quarterly earnings data on Wednesday, April 24th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of $0.93 by $0.19. The business had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.27 billion. Encompass Health had a net margin of 7.60% and a return on equity of 18.01%. The company’s revenue was up 13.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.88 earnings per share. On average, analysts anticipate that Encompass Health Co. will post 4.1 earnings per share for the current fiscal year.

Encompass Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Investors of record on Monday, July 1st will be paid a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 0.70%. The ex-dividend date is Friday, June 28th. Encompass Health’s dividend payout ratio (DPR) is presently 16.22%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. QRG Capital Management Inc. boosted its stake in shares of Encompass Health by 23.4% in the 1st quarter. QRG Capital Management Inc. now owns 7,738 shares of the company’s stock valued at $639,000 after purchasing an additional 1,467 shares in the last quarter. Inspire Investing LLC boosted its position in Encompass Health by 75.4% in the first quarter. Inspire Investing LLC now owns 34,470 shares of the company’s stock valued at $2,847,000 after buying an additional 14,818 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in Encompass Health in the first quarter valued at approximately $816,000. Tectonic Advisors LLC grew its stake in shares of Encompass Health by 12.0% during the first quarter. Tectonic Advisors LLC now owns 6,262 shares of the company’s stock worth $517,000 after buying an additional 672 shares during the last quarter. Finally, Oppenheimer & Co. Inc. increased its holdings in shares of Encompass Health by 5.6% during the first quarter. Oppenheimer & Co. Inc. now owns 118,201 shares of the company’s stock worth $9,761,000 after buying an additional 6,280 shares in the last quarter. Institutional investors own 97.25% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on EHC. Stephens reiterated an “overweight” rating and set a $85.00 price objective on shares of Encompass Health in a research note on Tuesday, January 16th. Raymond James reiterated a “strong-buy” rating and issued a $95.00 price target (up previously from $85.00) on shares of Encompass Health in a research note on Friday, April 26th. Barclays boosted their price objective on shares of Encompass Health from $101.00 to $108.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. Truist Financial raised their target price on shares of Encompass Health from $82.00 to $86.00 and gave the company a “buy” rating in a research note on Friday, February 9th. Finally, William Blair reissued an “outperform” rating on shares of Encompass Health in a research report on Wednesday, February 7th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $90.29.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.